Lung cancer after neoadjuvant therapy: Difference between revisions

Jump to navigation Jump to search
← Older edit
Michael (talk | contribs)
49,358 edits
No edit summary
Michael (talk | contribs)
49,358 edits
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref>
'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref>
==Major pathologic response==
:<math>V ={ {T} \over {B} } \times 100 \%</math>
Where:
:V = percent viable tumour.
:T = tumour area.
:B = tumour bed area.
Major pathologic response is defined as: V <=10%.
==Sign out==
<pre>
At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16). 
The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1] 
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
</pre>
===At cut-off value for major pathology response===
<pre>
The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1]  Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured.
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
</pre>


==See also==
==See also==
*[[Neoadjuvant therapy]].
*[[Neoadjuvant therapy]].
*[[Residual cancer burden index]].


==References==
==References==
Retrieved from "https://librepathology.org/wiki/Lung_cancer_after_neoadjuvant_therapy"